What did @ravyn.autumn actually say?
The creator recommended two peptides she'd start over with: retatrutide and GHK-Cu. She described retatrutide as "a GLP3" that is "incredible for weight loss" and cited a wave of emerging research on brain health, inflammation, liver function, and joint pain. For GHK-Cu, she pointed to anti-aging and tissue repair benefits, claiming it makes you "externally look more youthful and rejuvenated" while working internally on the same processes. She wrapped by saying combining the two would make you "feel like the best version of yourself."
That's a lot packed into a short video, and some of it deserves closer scrutiny. The classification claim in particular is worth stopping on immediately.
Does the science back this up?
On retatrutide, the research is genuinely interesting but still early-stage. On GHK-Cu, the evidence base is real but narrower than suggested. The "GLP3" label, though, is flatly wrong, and that's not a minor slip.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. It is sometimes informally called a GLP-1/GIP/glucagon tri-agonist, but "GLP3" is not a recognized pharmacological term. GLP-2 is a distinct gut peptide. There is no established receptor class called GLP3. Calling it that is either a misremembering of the mechanism or a simplification that slides into misinformation at 806,000 views.
The weight loss data is real. A Phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine) showed participants lost up to 24.2% of body weight over 48 weeks, which is striking. Preclinical data on inflammation and liver fat also exists, though most of this is in animal models or early human trials. The brain health claims are the weakest, with most evidence still in preclinical stages.
For GHK-Cu, Pickart and Margolina (2018, Cosmetics) documented its role in skin remodeling, collagen stimulation, and antioxidant activity. Real effects, but mostly in in vitro and small topical studies. The systemic anti-aging claims extrapolate well beyond what the controlled evidence actually shows.
What did they get wrong (or right)?
The "GLP3" label is wrong. Full stop. Retatrutide is a GIP, GLP-1, and glucagon receptor tri-agonist. Misclassifying the mechanism of a drug that is still in clinical trials and not FDA-approved for commercial use is not a harmless shorthand. It muddies what someone researching this would actually find, and it makes the video harder to trust overall.
The enthusiasm around retatrutide's broader effects, "tons and tons of studies," overstates where the science actually is. Most published data beyond weight loss is preclinical or observational. That's not nothing, but it's not "tons and tons."
Where the creator gets partial credit: the general premise that retatrutide has an unusually broad mechanism compared to older GLP-1 drugs is accurate. The glucagon receptor component does appear to have meaningful effects on liver fat and energy expenditure (Coskun et al., 2022, Cell Metabolism). And GHK-Cu's skin and tissue repair properties do have a legitimate published foundation, even if systemic benefits are overstated here.
The advice to start simple, "you don't need to invest in 50 different peptides," is actually reasonable harm reduction compared to the stacking rabbit holes common in this space.
What should you actually know?
Retatrutide is not available as a retail or consumer peptide product in an FDA-approved form. It is in Phase 3 clinical trials as of 2024. Anything being sold under this name in the gray-market peptide space is unregulated, unverified for purity, and carries real safety unknowns. The clinical trial results are promising, but that is not the same as saying the compound you can actually purchase is safe or equivalent.
GHK-Cu is more accessible, used topically in cosmetic products and studied more extensively in that form. Systemic injectable use is a different matter with much thinner human data.
Neither compound should be used without medical supervision. The creator invites people to DM her for guidance, which is not a substitute for a licensed clinician who can assess your health history, current medications, and specific risk profile. If you are interested in either compound, that conversation starts with a prescribing physician, not a comment section.
- Retatrutide does not have a commercially approved form yet. Phase 3 trials are ongoing.
- GHK-Cu has solid topical evidence. Systemic benefits in humans are still largely theoretical.
- "GLP3" is not a recognized pharmacological classification for retatrutide.